Prelude Strikes Exclusive Incyte Pact on JAK2 Inhibitors Amid 54% Stock Slump
By ATTN Desk · Editorial oversight: Sean Han
Prelude Therapeutics Inc. Overview
Prelude Therapeutics Inc. (NASDAQ: PRLD) is a clinical-stage precision oncology company headquartered in Wilmington, Delaware. Founded in 2016, it focuses on developing small-molecule degraders and inhibitors that target genomically defined cancers. Its pipeline includes SMARCA2 degraders, KAT6A degraders, CDK9 and CDK4/6 inhibitors, and next-generation degrader antibody conjugates (Precision ADCs).
Corporate Structure
Prelude employs between 51 and 200 people, drawing expertise from both start-up culture and experienced professionals in drug development. Leadership includes Kris Vaddi, Ph.D. (CEO), Peggy Scherle, Ph.D. (CSO), and Aimee Crombie (SVP, Strategic Planning and Operations). The company collaborates with partners such as AbCellera and Incyte to advance its therapeutic platforms.
Precision oncology by National Cancer Institute
Developments and News
On November 4, 2025, Prelude announced an exclusive option agreement with Incyte to advance mutant-selective JAK2V617F JH2 inhibitors. The company plans to present preclinical data at the American Society of Hematology (ASH) annual meeting in December 2025.
On October 15, 2025, Katina Dorton joined the Board of Directors, succeeding Mardi C. Dier. In a September 2025 filing, Prelude indicated it completed the Phase 1 dose escalation of PRT3789 (IV SMARCA2 degrader) both as monotherapy and in combination with docetaxel, and initiated its oral SMARCA2 program, PRT7732, in Q4 2024.
Second-quarter 2025 results noted advancements in core programs, including the progression of PRT3789, enrollment of the seventh dose cohort of PRT7732 (125 mg), and a planned KAT6A degrader IND filing in the first half of 2026. First-quarter 2025 disclosures included preclinical KAT6A data at the American Association for Cancer Research (AACR) Annual Meeting and updates on mCALR-targeted ADCs in collaboration with AbCellera.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (Nov 3, 2025 close) | $1.80 |
| Intraday Change | –54.77% |
| Volume | 8,477,740 |
| 52-Week Range | $0.61 – $4.22 |
| Market Capitalization | ~$225 million |
| Revenue (TTM) | $7 million |
| Net Income (TTM) | –$124.3 million |
| Cash & Cash Equivalents (MRQ) | $73.2 million |
| Total Debt/Equity (MRQ) | 23.6% |
| EPS (TTM) | –$1.64 |
| Return on Assets (TTM) | –49.8% |
| Price/Sales (TTM) | 15.6 |
| Price/Book (MRQ) | 1.07 |
Prelude's model, which heavily relies on research and development, contributes to negative profitability and a high burn rate relative to its limited revenue. The company’s cash runway is contingent on ongoing funding or partnerships. The agreement with Incyte and collaborations with AbCellera may mitigate development risks and potentially provide non-dilutive capital.
Market Position and Industry Context
As a precision oncology firm, Prelude competes with both larger pharmaceutical and biotechnology companies that are also advancing targeted degraders and ADCs. The industry trend toward targeted protein degradation and next-generation ADCs aligns with Prelude's capabilities, though regulatory challenges and clinical trial outcomes remain significant factors. Strong partnerships and milestone-driven collaborations are essential for managing risks and extending financial runway.
TL;DR
- November 4, 2025: Exclusive option agreement with Incyte on JAK2V617F JH2 inhibitors.
- December 2025: Preclinical data presentations at ASH.
- H1 2026: Expected IND filing for KAT6A degrader.
- Q2 2025: Completion of PRT3789 Phase 1 dose escalation; PRT7732 enrollment ongoing.
- Stock closed at $1.80 on November 3, 2025, down 54.77% intraday; market cap ~$225 million.
- Cash balance of $73.2 million vs. TTM net loss of $124.3 million; partnership agreements are key to funding future milestones.